Business
Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting
New clinical data from the SYMON-I study to evaluate IL-6 and organ dysfunction in sepsis patients to be presented.ACTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient tests for critical care conditions, today announced that an abstract related to its Symphony™ IL-6 Test has been accepted for presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual M
About this update from Bluejay Diagnostics, Inc.
[{"type":"image","alt":"Bluejay Diagnostics, Inc.","displaySize":"","headline":null,"caption":"Bluejay Diagnostics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/97303deb2c9a2ba3f4da1f553026db16"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BXZ.wc2RIKHwfdBTD44Jaw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTYyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/97303deb2c9a2ba3f4da1f553026db16","width":150,"height":44}},"lazy":false},{"type":"text","content":"New clinical data from the SYMON-I study to evaluate IL-6 and organ dysfunction in sepsis patients to be presented.","length":115,"tagName":"p"},{"type":"text","content":"ACTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient tests for critical care conditions, today announced that an abstract related to its Symphony™ IL-6 Test has been accepted for presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting, which will take place May 18–21, 2026 in Atlanta, Georgia.","length":456,"tagName":"p"},{"type":"text","content":"The presentation will report findings from SYMON-I, a multicenter pilot clinical study evaluating interleukin-6 (IL-6) levels in patients with sepsis who were admitted or intended for admission to the intensive care unit (ICU). The analysis evaluates the relationship between IL-6 levels measured in the emergency department and organ dysfunction as assessed by Sequential Organ Failure Assessment (SOFA) scores during the first three days of hospitalization.","length":459,"tagName":"p"},{"type":"text","content":"Nathan Shapiro, M.D., Vice Chairman of Emergency Medicine Research at Beth Israel Deaconess Medical Center and Professor of Emergency Medicine at Harvard Medical School and the clinical trial national principal investigator, stated:","length":232,"tagName":"p"},{"type":"text","content":"“The findings from the SYMON-I study suggest that IL-6 measured in the emergency department may be associated with subsequent organ dysfunction in patients with sepsis and septic shock. These data contribute to the growing body of evidence evaluating IL-6 as a potential biomarker in the early assessment of critically ill patients.”","length":...